Clinical Trials

Dr. Graff-Radford has participated in over 30 clinical trials for degenerative dementia syndromes and served as a member of the National Institutes of Health-funded Alzheimer's Disease Cooperative Study (ADCS) and the Alzheimer's Clinical Trials Consortium (ACTC), serving on the advisory committee.

Current clinical trials

• Plasmapheresis Versus Plasma Infusion From Young APOE3 Homozygotes into MCI APOE4 Homozygotes to Slow Disease Progression. In collaboration with Guojun Bu, Ph.D., and Abba C. Zubair, M.D., Ph.D., Dr. Graff-Radford is investigating the safety of plasma infusion or exchange in people with APOE.
• Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss (A4). The A4 study is investigating the effect of anti-amyloid treatment for cognitively normal people who have a positive amyloid PET scan.
• A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease (Generation S1). A randomized, double-blind, placebo-controlled, parallel group study evaluating the efficacy of CAD106 and for people at risk of the onset of clinical symptoms of Alzheimer's disease. The goal of this study is to prevent ApoE4 homozygotes from developing dementia using immunization or beta-secretase inhibitors.
• A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer's Disease. A study that seeks to evaluate the efficacy and safety of ABBV-8E12 in people with early-onset Alzheimer's disease.

Mayo Clinic also has thousands of other active clinical trials and research, and it coordinates national clinical trials with other medical institutions.

• Find clinical trials related to memory disorders.
• Explore all clinical trials at Mayo Clinic.
• Learn about volunteering in a clinical trial.